文献速递乳腺外科

SENOMIC试验首次结果:乳腺癌前哨淋巴结微转移省略腋窝淋巴结清扫

Omitting completion axillary lymph node dissection after detection of sentinel node micrometastases in breast cancer: first results from the prospective SENOMIC trial.
PubMed 文献 · Br J Surg · 2021-01-01

SENOMIC前瞻性多中心队列 trial 纳入566例乳腺癌伴前哨淋巴结微转移患者,省略完成性腋窝淋巴结清扫,中位随访38个月,3年无事件生存率96.2%,乳房切除组低于保乳组(93.8% vs 97.8%,P=0.011)。

要点

  • 乳腺癌前哨淋巴结微转移省略腋窝清扫后3年无事件生存率达96.2%。
  • 乳房切除组3年无事件生存率低于保乳组(93.8% vs 97.8%,P=0.011)。
  • 未接受辅助放疗的乳房切除患者复发风险显著高于保乳患者(HR 2.91,95%CI 1.25-6.75)。

核心结论

  • 乳腺癌伴前哨淋巴结微转移患者省略腋窝淋巴结清扫后3年无事件生存率良好。
  • 长期随访和继续入组乳房切除患者(尤其未接受辅助放疗者)至关重要。

研究设计与样本

  • 不进行完成性腋窝淋巴结清扫,主要终点为无事件生存,计划入组452例,最终纳入566例,中位随访38个月(范围7-67)。

主要发现

  • 3年无事件生存率为96.2%,基于26例报告的乳腺癌复发,包括5例孤立腋窝复发。
  • 乳房切除组与保乳组3年无事件生存率分别为93.8%和97.8%(P=0.011)。
  • 乳房切除患者肿瘤特征显著更差。
  • 单因素Cox回归显示,未接受辅助放疗的乳房切除患者复发风险显著高于保乳患者(HR 2.91,95%CI 1.25-6.75)。

临床怎么用

  • 对于乳腺癌伴前哨淋巴结微转移患者,可考虑省略完成性腋窝淋巴结清扫。
  • 乳房切除术后未接受辅助放疗的患者需加强随访和个体化评估。

局限性

  • 中位随访仅38个月,长期结果待进一步随访。
  • 乳房切除患者入组不足,需继续入组以确认安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Completion axillary lymph node dissection has been abandoned widely among patients with breast cancer and sentinel lymph node micrometastases, based on evidence from prospective RCTs. Inclusion in these trials has been subject to selection bias, with patients undergoing mastectomy being under-represented. The aim of the SENOMIC (omission of axillary lymph node dissection in SENtinel NOde MICrometases) trial was to confirm the safety of omission of axillary lymph node dissection in patients with breast cancer and sentinel lymph node micrometastases, and including patients undergoing mastectomy. METHODS: The prospective SENOMIC multicentre cohort trial enrolled patients with breast cancer and sentinel lymph node micrometastases who had breast-conserving surgery or mastectomy at one of 23 Swedish hospitals between October 2013 and March 2017. No completion axillary lymph node dissection was performed. The primary endpoint was event-free survival, with a trial accrual target of 452 patients. Survival proportions were based on Kaplan-Meier survival estimates. RESULTS: The trial included 566 patients. Median follow-up was 38 (range 7-67) months. The 3-year event-free survival rate was 96.2 per cent, based on 26 reported breast cancer recurrences, including five isolated axillary recurrences. The unadjusted 3-year event-free survival rate was higher than anticipated, but differed between patients who had mastectomy and those who underwent breast-conserving surgery (93.8 versus 97.8 per cent respectively; P = 0.011). Patients who underwent mastectomy had significantly worse tumour characteristics. On univariable Cox proportional hazards regression analysis, patients who had mastectomy without adjuvant radiotherapy had a significantly higher risk of recurrence than those who underwent breast-conserving surgery (hazard ratio 2.91, 95 per cent c.i. 1.25 to 6.75). CONCLUSION: After 3 years, event-free survival was excellent in patients with breast cancer and sentinel node micrometastases despite omission of axillary lymph node dissection. Long-term follow-up and continued enrolment of patients having mastectomy, especially those not receiving adjuvant radiotherapy, are of utmost importance.

来源:Br J Surg,查看原文。版权归原作者所有。

引用

  1. Andersson Y, Bergkvist L, Frisell J, et al. Omitting completion axillary lymph node dissection after detection of sentinel node micrometastases in breast cancer: first results from the prospective SENOMIC trial. Br J Surg. 2021. PMID: 34010418. doi:10.1093/bjs/znab141

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。